

# Biologics and Biosimilars-United States Market Status and Trend Report 2015-2026

<https://marketpublishers.com/r/B3A7CA51122EN.html>

Date: September 2020

Pages: 140

Price: US\$ 3,480.00 (Single User License)

ID: B3A7CA51122EN

## Abstracts

### Report Summary

Biologics and Biosimilars-United States Market Status and Trend Report 2015-2026 offers a comprehensive analysis on Biologics and Biosimilars industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole United States and Regional Market Size of Biologics and Biosimilars 2015-2019, and development forecast 2020-2026

Main market players of Biologics and Biosimilars in United States, with company and product introduction, position in the Biologics and Biosimilars market

Market status and development trend of Biologics and Biosimilars by types and applications

Cost and profit status of Biologics and Biosimilars, and marketing status

Market growth drivers and challenges Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium Biologics and Biosimilars market in 2020. COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing

panic among the population, and uncertainty about future. This report also analyses the impact of Coronavirus COVID-19 on the Biologics and Biosimilars industry.

The report segments the United States Biologics and Biosimilars market as:

United States Biologics and Biosimilars Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2015-2026):

New England

The Middle Atlantic

The Midwest

The West

The South

Southwest

United States Biologics and Biosimilars Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2015-2026):

Monoclonal Antibodies

Interferon

Erythropoietin

Insulin

Vaccines

Others

United States Biologics and Biosimilars Market: Application Segment Analysis (Consumption Volume and Market Share 2015-2026; Downstream Customers and Market Analysis)

Tumor

Diabetes

Cardiovascular

Hemophilia

Others

United States Biologics and Biosimilars Market: Players Segment Analysis (Company and Product introduction, Biologics and Biosimilars Sales Volume, Revenue, Price and Gross Margin):

Roche

Eli Lilly

Sanofi-Aventis

Amgen

Novo Nordisk  
AbbVie  
Merck  
Pfizer  
Johnson & Johnson  
Novartis  
Gelgen  
Ganlee  
3sbio  
Innovent  
Biotech  
Changchun High Tech  
Dong Bao  
CP Guojian

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF BIOLOGICS AND BIOSIMILARS**

- 1.1 Definition of Biologics and Biosimilars in This Report
- 1.2 Commercial Types of Biologics and Biosimilars
  - 1.2.1 Monoclonal Antibodies
  - 1.2.2 Interferon
  - 1.2.3 Erythropoietin
  - 1.2.4 Insulin
  - 1.2.5 Vaccines
  - 1.2.6 Others
- 1.3 Downstream Application of Biologics and Biosimilars
  - 1.3.1 Tumor
  - 1.3.2 Diabetes
  - 1.3.3 Cardiovascular
  - 1.3.4 Hemophilia
  - 1.3.5 Others
- 1.4 Development History of Biologics and Biosimilars
- 1.5 Market Status and Trend of Biologics and Biosimilars 2015-2026
  - 1.5.1 United States Biologics and Biosimilars Market Status and Trend 2015-2026
  - 1.5.2 Regional Biologics and Biosimilars Market Status and Trend 2015-2026

### **CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Biologics and Biosimilars in United States 2015-2019
- 2.2 Consumption Market of Biologics and Biosimilars in United States by Regions
  - 2.2.1 Consumption Volume of Biologics and Biosimilars in United States by Regions
  - 2.2.2 Revenue of Biologics and Biosimilars in United States by Regions
- 2.3 Market Analysis of Biologics and Biosimilars in United States by Regions
  - 2.3.1 Market Analysis of Biologics and Biosimilars in New England 2015-2019
  - 2.3.2 Market Analysis of Biologics and Biosimilars in The Middle Atlantic 2015-2019
  - 2.3.3 Market Analysis of Biologics and Biosimilars in The Midwest 2015-2019
  - 2.3.4 Market Analysis of Biologics and Biosimilars in The West 2015-2019
  - 2.3.5 Market Analysis of Biologics and Biosimilars in The South 2015-2019
  - 2.3.6 Market Analysis of Biologics and Biosimilars in Southwest 2015-2019
- 2.4 Market Development Forecast of Biologics and Biosimilars in United States 2020-2026
  - 2.4.1 Market Development Forecast of Biologics and Biosimilars in United States

2020-2026

2.4.2 Market Development Forecast of Biologics and Biosimilars by Regions

2020-2026

## **CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES**

3.1 Whole United States Market Status by Types

3.1.1 Consumption Volume of Biologics and Biosimilars in United States by Types

3.1.2 Revenue of Biologics and Biosimilars in United States by Types

3.2 United States Market Status by Types in Major Countries

3.2.1 Market Status by Types in New England

3.2.2 Market Status by Types in The Middle Atlantic

3.2.3 Market Status by Types in The Midwest

3.2.4 Market Status by Types in The West

3.2.5 Market Status by Types in The South

3.2.6 Market Status by Types in Southwest

3.3 Market Forecast of Biologics and Biosimilars in United States by Types

## **CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

4.1 Demand Volume of Biologics and Biosimilars in United States by Downstream Industry

4.2 Demand Volume of Biologics and Biosimilars by Downstream Industry in Major Countries

4.2.1 Demand Volume of Biologics and Biosimilars by Downstream Industry in New England

4.2.2 Demand Volume of Biologics and Biosimilars by Downstream Industry in The Middle Atlantic

4.2.3 Demand Volume of Biologics and Biosimilars by Downstream Industry in The Midwest

4.2.4 Demand Volume of Biologics and Biosimilars by Downstream Industry in The West

4.2.5 Demand Volume of Biologics and Biosimilars by Downstream Industry in The South

4.2.6 Demand Volume of Biologics and Biosimilars by Downstream Industry in Southwest

4.3 Market Forecast of Biologics and Biosimilars in United States by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BIOLOGICS AND BIOSIMILARS**

5.1 United States Economy Situation and Trend Overview

5.2 Biologics and Biosimilars Downstream Industry Situation and Trend Overview

## **CHAPTER 6 BIOLOGICS AND BIOSIMILARS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES**

6.1 Sales Volume of Biologics and Biosimilars in United States by Major Players

6.2 Revenue of Biologics and Biosimilars in United States by Major Players

6.3 Basic Information of Biologics and Biosimilars by Major Players

6.3.1 Headquarters Location and Established Time of Biologics and Biosimilars Major Players

6.3.2 Employees and Revenue Level of Biologics and Biosimilars Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

## **CHAPTER 7 BIOLOGICS AND BIOSIMILARS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

7.1 Roche

7.1.1 Company profile

7.1.2 Representative Biologics and Biosimilars Product

7.1.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Roche

7.2 Eli Lilly

7.2.1 Company profile

7.2.2 Representative Biologics and Biosimilars Product

7.2.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Eli Lilly

7.3 Sanofi-Aventis

7.3.1 Company profile

7.3.2 Representative Biologics and Biosimilars Product

7.3.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Sanofi-Aventis

7.4 Amgen

7.4.1 Company profile

- 7.4.2 Representative Biologics and Biosimilars Product
- 7.4.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Amgen
- 7.5 Novo Nordisk
  - 7.5.1 Company profile
  - 7.5.2 Representative Biologics and Biosimilars Product
  - 7.5.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Novo Nordisk
- 7.6 AbbVie
  - 7.6.1 Company profile
  - 7.6.2 Representative Biologics and Biosimilars Product
  - 7.6.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of AbbVie
- 7.7 Merck
  - 7.7.1 Company profile
  - 7.7.2 Representative Biologics and Biosimilars Product
  - 7.7.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Merck
- 7.8 Pfizer
  - 7.8.1 Company profile
  - 7.8.2 Representative Biologics and Biosimilars Product
  - 7.8.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Pfizer
- 7.9 Johnson & Johnson
  - 7.9.1 Company profile
  - 7.9.2 Representative Biologics and Biosimilars Product
  - 7.9.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Johnson & Johnson
- 7.10 Novartis
  - 7.10.1 Company profile
  - 7.10.2 Representative Biologics and Biosimilars Product
  - 7.10.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Novartis
- 7.11 Gelgen
  - 7.11.1 Company profile
  - 7.11.2 Representative Biologics and Biosimilars Product
  - 7.11.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Gelgen
- 7.12 Ganlee
  - 7.12.1 Company profile
  - 7.12.2 Representative Biologics and Biosimilars Product
  - 7.12.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Ganlee
- 7.13 3sbio
  - 7.13.1 Company profile
  - 7.13.2 Representative Biologics and Biosimilars Product

- 7.13.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of 3sbio
- 7.14 Innovent
  - 7.14.1 Company profile
  - 7.14.2 Representative Biologics and Biosimilars Product
  - 7.14.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Innovent
- 7.15 Biotech
  - 7.15.1 Company profile
  - 7.15.2 Representative Biologics and Biosimilars Product
  - 7.15.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Biotech
- 7.16 Changchun High Tech
- 7.17 Dong Bao
- 7.18 CP Guojian

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOLOGICS AND BIOSIMILARS**

- 8.1 Industry Chain of Biologics and Biosimilars
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BIOLOGICS AND BIOSIMILARS**

- 9.1 Cost Structure Analysis of Biologics and Biosimilars
- 9.2 Raw Materials Cost Analysis of Biologics and Biosimilars
- 9.3 Labor Cost Analysis of Biologics and Biosimilars
- 9.4 Manufacturing Expenses Analysis of Biologics and Biosimilars

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF BIOLOGICS AND BIOSIMILARS**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client



10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

## I would like to order

Product name: Biologics and Biosimilars-United States Market Status and Trend Report 2015-2026

Product link: <https://marketpublishers.com/r/B3A7CA51122EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B3A7CA51122EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970